Unum Therapeutics has relocated and expanded to 33,000 square feet of office and lab space at 200 Cambridgepark Drive in Cambridge’s Alewife neighborhood.

The company, which develops cellular immunotherapy treatments for cancer, last year received $65 million in Series B financing from investors led by New Leaf Venture Partners. It’s expanding its workforce to more than 80 employees after outgrowing its previous space at the 28,000-square-foot LabCentral incubator in Cambridge’s Kendall Square. The open office design is meant to foster collaboration among employees, and the site offers easy access to the MBTA’s Red Line, Unum said.

“To reach our full potential, we need to continue recruiting top-level talent. This move allows us to expand our hiring efforts within the world-class Cambridge life sciences hub, to house a larger team of scientists, and to continue to leverage our proximity to leading research and academic institutions and health care companies,” CEO Chuck Wilson said in a statement.

200 Cambridgepark Drive is part of a former Pfizer lab complex acquired by Cambridge-based King Street Properties in July 2014 for $40 million. King Street spent $44 million upgrading the 221,676-square-foot building, which is now 99 percent leased to life science tenants. Morgan Stanley Real Estate Investing acquired the property for $165.5 million on Dec. 31.